Lipoatrophy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Kiran Singh, M.D. [2]

Overview

Lipoatrophy is the term describing the localized loss of fat tissue. This may occur as a result of subcutanous injections of insulin in the treatment of diabetes, or from subcutanous injections of Copaxone used for the treatment of multiple sclerosis. In the latter case, an injection may produce a small dent at the injection site.^[1] Lipoatrophy is also an adverse drug reaction that is associated with some antiretroviral drugs.^[2]

Diagnosis

Physical Examination

Skin

Scalp

Postherpertic lipoatrophy. Adapted from Dermatology Atlas.^[3]
Postherpertic lipoatrophy. Adapted from Dermatology Atlas.^[3]
Postherpertic lipoatrophy. Adapted from Dermatology Atlas.^[3]
Postherpertic lipoatrophy. Adapted from Dermatology Atlas.^[3]

References

↑ Radermecker RP, Piérard GE, Scheen AJ (2007). “Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs”. American journal of clinical dermatology. 8 (1): 21–8. PMID 17298103.
↑ Barbaro G (2007). “Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome”. Curr. Pharm. Des. 13 (21): 2208–13. PMID 17627554.
↑ ^3.0 ^3.1 ^3.2 ^3.3 “Dermatology Atlas”.

Template:WikiDoc Sources

[1] Radermecker RP, Piérard GE, Scheen AJ (2007). “Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs”. American journal of clinical dermatology. 8 (1): 21–8. PMID 17298103.

[2] Barbaro G (2007). “Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome”. Curr. Pharm. Des. 13 (21): 2208–13. PMID 17627554.

[Dermatology_Atlas-3] 3.0 ^3.1 ^3.2 ^3.3 “Dermatology Atlas”.

[1]

[2]

[3]